@n0r0zha.bsky.social
MD | Clinical Researcher
Employee @LLUMC
📍SoCal
Employee @LLUMC
📍SoCal
Pinned
Reposted
New findings suggest a steady increase in the prevalence of kidney failure with replacement therapy worldwide over the past 3 decades. Read more in #ASNKidneyNews kidney.pub/KN1710-24
November 16, 2025 at 3:00 PM
New findings suggest a steady increase in the prevalence of kidney failure with replacement therapy worldwide over the past 3 decades. Read more in #ASNKidneyNews kidney.pub/KN1710-24
Reposted
2025 AJKD Editors' Choice Award winning article: Genetic Characterization of Kidney Failure of Unknown Etiology in Spain: Findings From the GENSEN Study
bit.ly/3WeEZ72
#VisualAbstract
bit.ly/3WeEZ72
#VisualAbstract
November 16, 2025 at 5:01 PM
2025 AJKD Editors' Choice Award winning article: Genetic Characterization of Kidney Failure of Unknown Etiology in Spain: Findings From the GENSEN Study
bit.ly/3WeEZ72
#VisualAbstract
bit.ly/3WeEZ72
#VisualAbstract
Reposted
📖 This weekend don't miss our @kidneyint.bsky.social #ISNFridaySelection: Patient preferences for kidney failure treatments www.kidney-internati...
November 16, 2025 at 5:09 PM
📖 This weekend don't miss our @kidneyint.bsky.social #ISNFridaySelection: Patient preferences for kidney failure treatments www.kidney-internati...
November 12, 2025 at 6:57 AM
November 11, 2025 at 5:50 AM
Artificial Intelligence in ADPKD: Transforming Diagnosis, Risk Stratification, and Therapeutic Interventions
SA-PO0555 : Journal of the American Society of Nephrology #KidneyWk
journals.lww.com/jasn/fulltex...
SA-PO0555 : Journal of the American Society of Nephrology #KidneyWk
journals.lww.com/jasn/fulltex...
journals.lww.com
November 2, 2025 at 4:24 PM
Artificial Intelligence in ADPKD: Transforming Diagnosis, Risk Stratification, and Therapeutic Interventions
SA-PO0555 : Journal of the American Society of Nephrology #KidneyWk
journals.lww.com/jasn/fulltex...
SA-PO0555 : Journal of the American Society of Nephrology #KidneyWk
journals.lww.com/jasn/fulltex...
Did you know Women in Nephrology offers a Mentor Match program? Whether you want to be a mentor or find one, WIN helps you connect with your perfect match. If you are a member, apply today!
#WIN #MentorMatch
#WIN #MentorMatch
October 31, 2025 at 6:50 AM
Did you know Women in Nephrology offers a Mentor Match program? Whether you want to be a mentor or find one, WIN helps you connect with your perfect match. If you are a member, apply today!
#WIN #MentorMatch
#WIN #MentorMatch
Reposted
Executive summary of the #KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (#IgAN) and Immunoglobulin A Vasculitis (#IgAV)
doi.org/10.1016/j.kint.2025.04.003
#OpenAccess #MedSky #NephSky @kdigo.org
doi.org/10.1016/j.kint.2025.04.003
#OpenAccess #MedSky #NephSky @kdigo.org
October 21, 2025 at 6:53 PM
Executive summary of the #KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (#IgAN) and Immunoglobulin A Vasculitis (#IgAV)
doi.org/10.1016/j.kint.2025.04.003
#OpenAccess #MedSky #NephSky @kdigo.org
doi.org/10.1016/j.kint.2025.04.003
#OpenAccess #MedSky #NephSky @kdigo.org
Reposted
Core Curriculum by Craig E. Gordon et al:
Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2025
bit.ly/465twwK (FREE)
Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2025
bit.ly/465twwK (FREE)
October 21, 2025 at 10:01 PM
Core Curriculum by Craig E. Gordon et al:
Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2025
bit.ly/465twwK (FREE)
Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2025
bit.ly/465twwK (FREE)
Reposted
Empowering the Next Generation of Nephrologists: Trainee Opportunities in #GlomCon Ecosystem from @asnpublications.bsky.social @glomcon.org @bettercallseeth.bsky.social @saynanorouzi.bsky.social @nephrologista.bsky.social @poyanmehr.org
#Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/41105470/
#Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/41105470/
October 18, 2025 at 3:09 PM
Empowering the Next Generation of Nephrologists: Trainee Opportunities in #GlomCon Ecosystem from @asnpublications.bsky.social @glomcon.org @bettercallseeth.bsky.social @saynanorouzi.bsky.social @nephrologista.bsky.social @poyanmehr.org
#Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/41105470/
#Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/41105470/
Reposted
Did you miss #GlomCon Hawaii? Don't worry, I took the hit and flew to Hawaii for a week so I could give all of you a summary of what went down. Read all about it...
DON'T MISS Joel Topf's reflections on #GlomConHawaii (plus a few gorgeous photos!). www.docwirenews.com/post/glomcon... @kidneyboy.bsky.social #nephrology #nephsky #glomerulardisease #kidneydisease
GlomCon Hawaii Conference Highlights | Docwire News
Nephrology Times editorial board member Joel Topf, MD, gives his perspective on GlomCon Hawaii 2025, a conference on glomerular diseases.
www.docwirenews.com
October 16, 2025 at 3:34 PM
Did you miss #GlomCon Hawaii? Don't worry, I took the hit and flew to Hawaii for a week so I could give all of you a summary of what went down. Read all about it...
Thank you NKF for having us at the #NKFSoCalKidneyWalk 🧡
Today, we hosted a booth to recruit for our “Kidney Check” study, proudly sponsored by the IgAN Foundation.
Today, we hosted a booth to recruit for our “Kidney Check” study, proudly sponsored by the IgAN Foundation.
September 29, 2025 at 12:15 AM
Thank you NKF for having us at the #NKFSoCalKidneyWalk 🧡
Today, we hosted a booth to recruit for our “Kidney Check” study, proudly sponsored by the IgAN Foundation.
Today, we hosted a booth to recruit for our “Kidney Check” study, proudly sponsored by the IgAN Foundation.
Reposted
IgG4-related tubulointerstitial nephritis with negative contrast-enhanced computed tomography: diagnostic insights from 18F-fluorodeoxyglucose–positron emission tomography/computed tomography
doi.org/10.1016/j.kint.2025.02.031
#KINephrologyImage #NephSky #MedSky #KidneyPath #RenalPath #kidneybiopsy
doi.org/10.1016/j.kint.2025.02.031
#KINephrologyImage #NephSky #MedSky #KidneyPath #RenalPath #kidneybiopsy
July 9, 2025 at 4:18 PM
IgG4-related tubulointerstitial nephritis with negative contrast-enhanced computed tomography: diagnostic insights from 18F-fluorodeoxyglucose–positron emission tomography/computed tomography
doi.org/10.1016/j.kint.2025.02.031
#KINephrologyImage #NephSky #MedSky #KidneyPath #RenalPath #kidneybiopsy
doi.org/10.1016/j.kint.2025.02.031
#KINephrologyImage #NephSky #MedSky #KidneyPath #RenalPath #kidneybiopsy
Reposted
ALECT2 amyloidosis in a patient with myeloma cast nephropathy
Concomitant renal amyloidosis, typically AL, can be rarely seen in patients with myeloma cast nephropathy.
doi.org/10.1016/j.kint.2024.12.024
#NephSky #MedSky #NephrologyImage #renalpath #kidneypath #kidneybiopsy #multiplemyeloma
Concomitant renal amyloidosis, typically AL, can be rarely seen in patients with myeloma cast nephropathy.
doi.org/10.1016/j.kint.2024.12.024
#NephSky #MedSky #NephrologyImage #renalpath #kidneypath #kidneybiopsy #multiplemyeloma
July 14, 2025 at 1:31 PM
ALECT2 amyloidosis in a patient with myeloma cast nephropathy
Concomitant renal amyloidosis, typically AL, can be rarely seen in patients with myeloma cast nephropathy.
doi.org/10.1016/j.kint.2024.12.024
#NephSky #MedSky #NephrologyImage #renalpath #kidneypath #kidneybiopsy #multiplemyeloma
Concomitant renal amyloidosis, typically AL, can be rarely seen in patients with myeloma cast nephropathy.
doi.org/10.1016/j.kint.2024.12.024
#NephSky #MedSky #NephrologyImage #renalpath #kidneypath #kidneybiopsy #multiplemyeloma
Reposted
Artificial intelligence and perspective for rare genetic kidney diseases
Chen et al.
doi.org/10.1016/j.kint.2025.03.033
#OpenAccess #KIMiniReview #artificialintelligence
Find more articles in KI Kidney Genomic Medicine collection:
www.kidney-international.org/content/kidn...
Chen et al.
doi.org/10.1016/j.kint.2025.03.033
#OpenAccess #KIMiniReview #artificialintelligence
Find more articles in KI Kidney Genomic Medicine collection:
www.kidney-international.org/content/kidn...
July 30, 2025 at 3:52 PM
Artificial intelligence and perspective for rare genetic kidney diseases
Chen et al.
doi.org/10.1016/j.kint.2025.03.033
#OpenAccess #KIMiniReview #artificialintelligence
Find more articles in KI Kidney Genomic Medicine collection:
www.kidney-international.org/content/kidn...
Chen et al.
doi.org/10.1016/j.kint.2025.03.033
#OpenAccess #KIMiniReview #artificialintelligence
Find more articles in KI Kidney Genomic Medicine collection:
www.kidney-international.org/content/kidn...
Reposted
Executive summary of the #KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy ( #IgAN) and Immunoglobulin A Vasculitis ( #IgAV)
doi.org/10.1016/j.kint.2025.04.003
#OpenAccess #MedSky #NephSky #glomerulardisease @imperialcollegeldn.bsky.social
doi.org/10.1016/j.kint.2025.04.003
#OpenAccess #MedSky #NephSky #glomerulardisease @imperialcollegeldn.bsky.social
September 23, 2025 at 3:14 PM
Executive summary of the #KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy ( #IgAN) and Immunoglobulin A Vasculitis ( #IgAV)
doi.org/10.1016/j.kint.2025.04.003
#OpenAccess #MedSky #NephSky #glomerulardisease @imperialcollegeldn.bsky.social
doi.org/10.1016/j.kint.2025.04.003
#OpenAccess #MedSky #NephSky #glomerulardisease @imperialcollegeldn.bsky.social
Reposted
September 23, 2025 at 11:12 PM
Reposted
Is hepatotoxicity still a concern with long-term Tolvaptan use? This #ASNKidney360 review summarizes the data from clinical trials and presents real world evidence: kidney.pub/KID0934
August 30, 2025 at 4:00 PM
Is hepatotoxicity still a concern with long-term Tolvaptan use? This #ASNKidney360 review summarizes the data from clinical trials and presents real world evidence: kidney.pub/KID0934
Reposted
Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Assessing the Efficacy and Safety of Felzartamab for IgA Nephropathy
doi.org/10.1016/j.kint.2025.05.028
#OpenAccess #IgAN #felzartamab #IgANephropathy
doi.org/10.1016/j.kint.2025.05.028
#OpenAccess #IgAN #felzartamab #IgANephropathy
July 7, 2025 at 3:16 PM
Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Assessing the Efficacy and Safety of Felzartamab for IgA Nephropathy
doi.org/10.1016/j.kint.2025.05.028
#OpenAccess #IgAN #felzartamab #IgANephropathy
doi.org/10.1016/j.kint.2025.05.028
#OpenAccess #IgAN #felzartamab #IgANephropathy
Cardiovascular Complications in Autosomal Dominant Polycystic Kidney Disease - Kidney International Reports @kireports.bsky.social
www.kireports.org/article/S246...
www.kireports.org/article/S246...
Cardiovascular Complications in Autosomal Dominant Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease (ADPKD), primarily caused by mutations
in the PKD1 or PKD2 gene, is among the most common hereditary kidney diseases worldwide
and is associated with signi...
www.kireports.org
July 5, 2025 at 10:40 PM
Cardiovascular Complications in Autosomal Dominant Polycystic Kidney Disease - Kidney International Reports @kireports.bsky.social
www.kireports.org/article/S246...
www.kireports.org/article/S246...
Reposted
Amir Abdipour from #LomaLindaUniversityMedicalCenter discusses his study on the alignment of AI models with nephrologists when answering patient questions about #diabeticnephropathy.
Watch now: www.youtube.com/watch?v=yqDP...
Read the full article: diabetes.jmir.org/2025/1/e65846/
#AI #LLU
Watch now: www.youtube.com/watch?v=yqDP...
Read the full article: diabetes.jmir.org/2025/1/e65846/
#AI #LLU
AI vs. Nephrologists: Diabetic Nephropathy Q&A
This video reviews a cross-sectional study comparing how artificial intelligence models like ChatGPT and Google Gemini align with nephrologists when answerin...
www.youtube.com
June 23, 2025 at 2:04 PM
Amir Abdipour from #LomaLindaUniversityMedicalCenter discusses his study on the alignment of AI models with nephrologists when answering patient questions about #diabeticnephropathy.
Watch now: www.youtube.com/watch?v=yqDP...
Read the full article: diabetes.jmir.org/2025/1/e65846/
#AI #LLU
Watch now: www.youtube.com/watch?v=yqDP...
Read the full article: diabetes.jmir.org/2025/1/e65846/
#AI #LLU
Watch this one-minute video highlighting our paper published in @jmirpub.bsky.social
www.youtube.com/watch?v=yqDP...
www.youtube.com/watch?v=yqDP...
AI vs. Nephrologists: Diabetic Nephropathy Q&A
YouTube video by JMIR Publications
www.youtube.com
June 21, 2025 at 2:02 AM
Watch this one-minute video highlighting our paper published in @jmirpub.bsky.social
www.youtube.com/watch?v=yqDP...
www.youtube.com/watch?v=yqDP...
Reposted
Long-term data presented at #ERA25 on Thursday support the efficacy and safety of zigakibart for IgAN. #nephrology #nephsky #iganephropathy #igan www.docwirenews.com/post/long-te...
Long-Term Data Support Efficacy and Safety of Zigakibart for IgAN | Docwire News
Data from a phase 1/2 study demonstrated that the anti-APRIL zigakibart reduced proteinuria and stabilized kidney function of patients with IgA nephropathy (IgAN) at 100 weeks.
www.docwirenews.com
June 6, 2025 at 12:00 AM
Long-term data presented at #ERA25 on Thursday support the efficacy and safety of zigakibart for IgAN. #nephrology #nephsky #iganephropathy #igan www.docwirenews.com/post/long-te...
May 23, 2025 at 5:57 AM
Reposted
Real-world challenges in the use of tolvaptan for ADPKD lead to high discontinuation rates and dosage adjustments, underscoring the need for standardized and improved management strategies to enhance tolerability and adherence. https://bit.ly/KID0816
@shelliefravel.bsky.social
#ASNKidney360
@shelliefravel.bsky.social
#ASNKidney360
May 19, 2025 at 6:00 PM
Real-world challenges in the use of tolvaptan for ADPKD lead to high discontinuation rates and dosage adjustments, underscoring the need for standardized and improved management strategies to enhance tolerability and adherence. https://bit.ly/KID0816
@shelliefravel.bsky.social
#ASNKidney360
@shelliefravel.bsky.social
#ASNKidney360